Fate Therapeutics, Inc. (FATE) News
Track canonical SquawkNews coverage tagged to FATE, Fate Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Fate awarded $15M CIRM CLIN2 grant to fund Phase 2 RECLAIM-LN trial of FT819
Fate received a $15.0 million CIRM CLIN2 grant to support its Phase 2 RECLAIM-LN trial of FT819.Key Highlights:Original SEC Filing: FATE THERAPEUTICS INC [ FATE ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It ma
REGULATION | Sep 28, 2026, 12:16 PM UTC
L
Fate Therapeutics, Inc. (FATE) Wins $15M CIRM Grant for FT819 Phase 2 RECLAIM-LN
Fate Therapeutics received a $15.0M CIRM CLIN2 grant to support RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 off-the-shelf CAR T in refractory SLE with lupus nephritis.Material DetailsContext by AI Ana
NEWS | Sep 25, 2026, 11:01 AM UTC
L
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus NephritisCLIN2 Grant is a highly competitive award from CIRM to fund
NEWS | Sep 25, 2026, 11:01 AM UTC
L
FATE - Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
FATE - Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
NEWS | Sep 16, 2026, 11:00 AM UTC
M
FATE’s scalable CAR T platform shows promising Phase II lupus nephritis progress
Conference update from FATE highlights a scalable, cost-effective CAR T platform, with Phase II underway for FT819 in lupus nephritis and early results aimed at 30%-40% CRR.
EQUITY | Sep 09, 2026, 03:05 PM UTC
L
FATE’s FT819 CAR T shows promising early lupus nephritis efficacy
Fate’s phase II trial of FT819 in lupus nephritis is progressing, supported by a scalable master cell bank approach. The program targets a 30%-40% CRR, with key data readouts expected by early next year.
EQUITY | Sep 09, 2026, 02:41 PM UTC
L
Fate Therapeutics to present FT819 Encore clinical data at CCR West 2026
Fate Therapeutics said it will present encore clinical data for its FT819 off-the-shelf CAR T-cell product candidate at the CCR West 2026 meeting.
EQUITY | Sep 09, 2026, 11:01 AM UTC
L
Fate Therapeutics to join fireside chat at Cantor Global Healthcare 2026
Fate Therapeutics says it will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference.
EQUITY | Sep 03, 2026, 11:00 AM UTC
M
Fate Therapeutics starts potentially registrational RECLAIM-LN FT819 trial
Fate Therapeutics (FATE) initiates the potentially registrational RECLAIM-LN clinical trial of FT819 for the treatment of lupus nephritis.
EQUITY | Aug 14, 2026, 11:00 AM UTC
L
Fate Therapeutics reports Q2 2026 financial results and business updates
Fate Therapeutics (FATE) reports its second quarter 2026 financial results and provides business updates, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 12:31 PM UTC
L
Fate Therapeutics Reports New Employee Awards
Fate Therapeutics grants new employee inducement awards
EQUITY | Aug 03, 2026, 08:05 PM UTC
H
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq 100 futures gaining around 100 points on Wednesday. Shares of Phoenix Education Partners Inc (NYSE: PXED ) fell sharply in pre-market trading after the
EARNINGS | Jul 15, 2026, 12:02 PM UTC
L
Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839
() -- (Updates to add the latest stock move in the headline and the first paragraph.) Fate Therapeutics (FATE) shares were up more than 7% in Thursday trading after the US Food and Drug Administration approved the compan
REGULATION | Jul 09, 2026, 06:48 PM UTC
L
Fate Therapeutics announces FDA clearance of FT839 IND application
Fate Therapeutics announced that the FDA has cleared its investigational new drug, or IND, application for FT839, the company's next-generation, off-the-shelf CAR T-cell product candidate engineered to co-target CD19 and
EQUITY | Jul 09, 2026, 01:25 PM UTC
L
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISS
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage bio
EQUITY | Jul 06, 2026, 12:30 PM UTC